scholarly journals Bowman-Birk Protease Inhibitor as a Potential Oral Therapy for Multiple Sclerosis

10.5772/54066 ◽  
2013 ◽  
Author(s):  
Farinaz Safavi ◽  
Abdolmohamad Rostami
Keyword(s):  
Multiple Sclerosis ◽  
Protease Inhibitor ◽  
Oral Therapy

Oral Therapy for Multiple Sclerosis — Sea Change or Incremental Step?

2010 ◽  
Vol 362 (5) ◽  
pp. 456-458 ◽  
Author(s):  
William M. Carroll
Keyword(s):  
Multiple Sclerosis ◽  
Oral Therapy ◽  
Incremental Step

scholarly journals Fingolimod (FTY720): First approved oral therapy for multiple sclerosis

2011 ◽  
Vol 2 (1) ◽  
pp. 49 ◽  
Author(s):  
Sushil Sharma ◽  
AG Mathur ◽  
Sapna Pradhan ◽  
DB Singh ◽  
Sparsh Gupta
Keyword(s):  
Multiple Sclerosis ◽  
Oral Therapy

The effect of magnesium oral therapy on spasticity in a patient with multiple sclerosis

2000 ◽  
Vol 7 (6) ◽  
pp. 741-744 ◽  
Author(s):  
P. Rossier ◽  
S. van Erven ◽  
D. T. Wade
Keyword(s):  
Multiple Sclerosis ◽  
Oral Therapy

Oral therapy approved for multiple sclerosis

2013 ◽  
Vol 70 (9) ◽  
pp. 744-744
Author(s):  
Kate Traynor
Keyword(s):  
Multiple Sclerosis ◽  
Oral Therapy

BG00012 - A Novel Oral Therapy in Development for the Treatment of Multiple Sclerosis

2008 ◽  
Vol 3 (1) ◽  
pp. 99 ◽  
Author(s):  
Robert J Fox ◽  
Keyword(s):  
Multiple Sclerosis ◽  
Oral Therapy

scholarly journals Immune parameters of patients treated with laquinimod, a novel oral therapy for the treatment of multiple sclerosis: results from a double-blind placebo-controlled study

2015 ◽  
Vol 3 (2) ◽  
pp. 45-55 ◽  
Author(s):  
Mariusz Stasiolek ◽  
Ralf A. Linker ◽  
Liat Hayardeny ◽  
Oren Bar Ilan ◽  
Ralf Gold
Keyword(s):  
Multiple Sclerosis ◽  
Oral Therapy ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Immune Parameters

scholarly journals Ponesimod oral therapy for the treatment of relapsing forms of multiple sclerosis in adults and its precautions in cardiovascular disease patients

2021 ◽  
pp. 248-252
Author(s):  
Mohammed Alrouji
Keyword(s):  
Multiple Sclerosis ◽  
Heart Failure ◽  
Cardiovascular Disease ◽  
Oral Therapy ◽  
Decompensated Heart Failure ◽  
The United States ◽  
Class Iii ◽  
United States Food ◽  
Sphingosine 1 Phosphate ◽  
Ischemic Attack

The ponesimod oral therapy was approved in March 2021 by the United States Food and Drug Administration for relapsing forms multiple sclerosis (MS). Ponesimod is a sphingosine 1-phosphate (S1P) receptor 1 modulator that acts selectively as an anti- inflammatory agent and provides a suitable microenvironment for the function of the other neuroprotective agents. Ponesimod is contraindicated in patients who in the last 6 months, have experienced myocardial infarction, unstable angina, stroke, transient ischemic attack (TIA), decompensated heart failure requiring hospitalization, or Class III or IV heart failure. Also contraindicated in patients who have the presence of Mobitz type II second-degree, third-degree atrioventricular (AV) block, sick sinus syndrome, or sino-atrial block, unless the patient has a functioning pacemaker. This article briefs the information about dosage, precautions and warnings required in cardiovascular disease patients before initiation of ponesimod oral therapy.

scholarly journals Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study

2014 ◽  
Vol 3 (3) ◽  
pp. 341-349 ◽  
Author(s):  
Marcelo Kremenchutzky ◽  
Paul O’Connor ◽  
Reinhard Hohlfeld ◽  
Lixin Zhang-Auberson ◽  
Philipp von Rosenstiel ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Oral Therapy ◽  
Prior Treatment ◽  
Efficacy And Safety ◽  
Treatment Status ◽  
Subgroup Analyses
Sign in / Sign up

Export Citation Format

Share Document